Shuchi S. Pandya

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +8

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal et al. · New England Journal of Medicine · 2023 · 719 citations · Full text

Medicine, Neurology, Oncology +8

CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib

Daniel B. Costa, Susumu Kobayashi, Shuchi S. Pandya et al. · Journal of Clinical Oncology · 2011 · 590 citations · Full text

Medicine, Oncology, Pharmacology +17

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Pau Montesinos, Christian Récher, Susana Vives et al. · New England Journal of Medicine · 2022 · 483 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation

Andrew X. Zhu, Teresa Macarulla, Milind Javle et al. · JAMA Oncology · 2021 · 473 citations · Full text

Medicine, Oncology, Pharmacology +10